Novartis AG (NVS) DIvidends Date & History

Key Takeaways

• NVS pays an annual dividend of $4.74 per share, currently yielding roughly 3.2%.
• Dividends are paid once per year, a structure typical of Swiss-listed companies.
• The company has raised its dividend for six consecutive years, supported by a 30-plus-year payout track record.
• The payout ratio of about 66% to 71% of earnings appears sustainable and well covered by free cash flow.
• Novartis offers a moderate, above-average yield versus most large pharmaceutical peers.

Dividend Overview

Novartis AG is a Swiss pharmaceutical and healthcare company headquartered in Basel, Switzerland. Its shares trade in the United States as an American Depositary Receipt (ADR) under the ticker NVS, meaning U.S. investors hold a security that represents ownership in the underlying Swiss ordinary shares.

Novartis pays an annual dividend of $4.74 per ADR, which translates to a dividend yield of approximately 3.2%. The company distributes its dividend once per year rather than quarterly, a convention common among Swiss and European firms. The most recent dividend went ex-dividend on March 11, 2026, and was paid on March 16, 2026. With a moderate yield, a long payout history, and steady annual increases, Novartis is best characterized as a dividend growth stock rather than a pure high-yield play.

Dividend History and Growth

Novartis has maintained a consistent dividend program for more than three decades, having paid shareholders regularly since the 1990s. The company has increased its dividend for six consecutive years, reflecting management's commitment to returning capital to shareholders even as it reshapes its portfolio.

Recent payout growth has been solid. The dividend rose from $3.74 per share in 2024 to $3.99 in 2025, and then to $4.74 in 2026, an increase of roughly 18.7% in the latest cycle. Over the past five years, the dividend has compounded at a mid-to-high single-digit annual rate. Because the dividend is declared in Swiss francs and converted to U.S. dollars for ADR holders, the exact dollar amount can fluctuate with currency exchange rates. Still, the underlying trend is one of reliable, gradual growth rather than aggressive or volatile changes.

Dividend Sustainability and Payout Ratio

Novartis' dividend appears well supported. The payout ratio, which measures the share of earnings paid out as dividends, stands at roughly 66% to 71%. While that is not the lowest in the sector, it leaves a reasonable buffer of retained earnings for research and development, acquisitions, and share buybacks.

Cash flow coverage is a particular strength. The company's dividend consumes only about half of its free cash flow (FCF), the cash left over after operating and capital expenses, providing a comfortable margin of safety. Novartis also maintains a strong balance sheet with manageable debt relative to its earnings power. Following its 2023 spin-off of generic-drug maker Sandoz, Novartis has focused on higher-margin innovative medicines, which tends to support stable cash generation. Taken together, these factors suggest the dividend is sustainable and likely to keep growing modestly.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical space, Novartis' yield of about 3.2% is slightly above average. For context, JNJ (Johnson & Johnson) yields roughly 2.0% to 2.3%, MRK (Merck & Co.) around 2.3% to 3.0%, and Swiss rival RHHBY (Roche) near 2.8% to 3.0%. The notable outlier is PFE (Pfizer), which yields above 6%, though that elevated figure reflects a depressed share price rather than faster dividend growth.

Novartis therefore sits in a comfortable middle ground: a higher yield than most diversified peers, coupled with a payout ratio that is far more conservative than Pfizer's and broadly in line with, or better than, the industry norm.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending stocks, and breakout candidates more efficiently than manual screening, making it a practical companion for investors researching names like NVS alongside its peers. Explore the AI Screener to refine your search and uncover new opportunities.

Is This Stock Attractive for Dividend Investors?

Novartis is likely to appeal most to dividend growth investors and long-term, income-oriented investors who value consistency and gradual payout increases over maximum current yield. Its six-year streak of dividend hikes, three-decade payout history, and solid free cash flow coverage make it a candidate for investors seeking a dependable, slowly growing income stream.

The once-a-year payment schedule may be less convenient for income investors who prefer quarterly distributions, and the yield, while respectable, is not among the highest in the sector. Investors seeking maximum immediate income might look elsewhere, while those focused purely on rapid dividend growth may find faster-growing payers more attractive. However, for conservative, long-term investors who appreciate a financially stable, innovation-driven healthcare business with a rising dividend, Novartis offers a balanced profile of yield, growth, and stability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations